Sulfanilamide powder is a crystalline antimicrobial compound that was once sprinkled directly into open wounds to prevent bacterial infection, most famously on World War II battlefields. It belongs to the sulfonamide class of drugs, which work by blocking a step in the metabolic pathway bacteria use to make folate, a nutrient essential for their growth. The powder largely disappeared from clinical use because of a convergence of problems: bacteria developed widespread resistance to it, the drug caused serious and sometimes fatal side effects, and far more effective antibiotics arrived to take its place.
How Sulfanilamide Works Against Bacteria
Sulfanilamide targets an enzyme called dihydropteroate synthase, or DHPS, which bacteria need to produce folate from scratch. Human cells do not make their own folate; we get it from food. That difference is what made sulfonamides so appealing in the first place: the drug could starve bacteria of a critical nutrient without directly harming human metabolism. The compound is structurally similar to para-aminobenzoic acid, the natural molecule that DHPS normally grabs to begin folate synthesis. Sulfanilamide essentially tricks the enzyme into binding the wrong molecule, jamming the process.
This mechanism made sulfanilamide bacteriostatic rather than bactericidal. It did not kill bacteria outright; it stopped them from multiplying, giving the patient’s immune system time to clear the infection. That distinction matters, because it meant the drug worked best in patients whose immune function was intact and when the bacterial load was still manageable.
From Lab Curiosity to Medical Milestone
Sulfanilamide was first synthesized in 1908, but no one recognized its antibacterial potential for decades. It sat in obscurity until the 1930s, when Gerhard Domagk, working in the laboratory of the I. G. Farben chemical company in Germany, reported in 1935 that a related compound called prontosil was effective against streptococcal infections in mice.1JAMA. THE LOCAL USE OF SULFONAMIDE COMPOUNDS IN DERMATOLOGY Researchers soon discovered that prontosil was a prodrug: the body broke it down into sulfanilamide, which was the actual active ingredient. That realization opened the floodgates. Sulfanilamide was cheap, easy to manufacture, and effective against a range of bacteria that had previously been untreatable. Within a few years, it became one of the most widely prescribed drugs in the world.
Before sulfonamides arrived, physicians had almost no tools for bacterial infections beyond antiseptics and hoping for the best. A strep throat could progress to rheumatic fever; a wound infection could turn fatal. Sulfanilamide and its chemical relatives transformed that picture, particularly for infections caused by streptococci, staphylococci, and several other common pathogens.
Battlefield Use in World War II
Sulfanilamide powder became iconic during World War II. Allied soldiers carried individual packets of the powder in their first-aid kits and were trained to sprinkle it directly into open wounds before bandaging. The idea was simple: get the drug right into the tissue where bacteria were most likely to take hold. Military medics also used it extensively in field hospitals, and the drug was credited with reducing infection-related deaths among wounded troops.
The revolution in treatment brought about by sulfonamides had a deep effect on British and American wartime medicine, as the increased prevalence of wound infections among servicemen made antibacterial drugs a military priority.2Medical Humanities. The war against bacteria: how were sulphonamide drugs used by Britain during World War II? Sulfanilamide was not the only sulfonamide in use; sulfathiazole and sulfadiazine were also deployed. But the pure sulfanilamide powder applied topically to wounds became the version most embedded in popular memory, featured in war films and first-aid training manuals for decades afterward.
There were limitations even at the time, however. Surgeons noticed that the powder did not work well in heavily contaminated or pus-filled wounds. The biochemical explanation is straightforward: the very tissue debris and purulent discharge present in dirty wounds contains substances that compete with sulfanilamide for the bacterial enzyme, effectively neutralizing the drug at the site where it is most needed.3JAMA. SULFONAMIDE COMPOUNDS IN THE PREVENTION AND TREATMENT OF WOUND INFECTION: A CONSIDERATION OF THE PRINCIPLES WHICH GOVERN THEIR USE This meant that thorough wound debridement, removing dead tissue and foreign material before applying the powder, was critical. Without it, the sulfanilamide sat there doing little.
The Elixir Sulfanilamide Disaster
One of the most consequential episodes in pharmaceutical history involved sulfanilamide, though not the powder form. In 1937, a Tennessee drug company called S. E. Massengill began selling a liquid preparation marketed as “Elixir Sulfanilamide.” To dissolve the drug, the company’s chemist used diethylene glycol, a sweet-tasting solvent that also happens to be a potent kidney and liver poison. No safety testing was done. More than 100 people died after taking the product, many of them children.
The disaster exposed a glaring hole in American drug regulation. At the time, manufacturers were not required to demonstrate that a new drug was safe before selling it. The public outrage that followed the Elixir Sulfanilamide deaths directly prompted Congress to pass the 1938 Federal Food, Drug and Cosmetic Act, which for the first time required proof of safety before a new drug could be released to the market.4PubMed. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act That law became the foundation for modern drug regulation in the United States.5PubMed. Therapeutic disasters that hastened safety testing of new drugs
It is worth noting that the sulfanilamide itself was not the problem in this tragedy. The drug had already been widely used in tablet and powder form without the same lethal outcomes. The killer was diethylene glycol, chosen purely because it dissolved the drug nicely and tasted pleasant. But the episode permanently linked the name “sulfanilamide” to a cautionary tale about pharmaceutical negligence, and it accelerated both public skepticism and regulatory scrutiny of the entire drug class.
Serious Side Effects
Even when sulfanilamide was used correctly, it carried real risks that became harder to justify as safer alternatives appeared. These side effects affected multiple organ systems and ranged from uncomfortable to life-threatening.
Blood Disorders
Sulfonamides, including sulfanilamide, can cause methemoglobinemia, a condition in which hemoglobin is altered so it can no longer carry oxygen efficiently. Patients develop a characteristic bluish skin color and can become dangerously hypoxic. A case report documented a patient whose methemoglobin level climbed to 26% after exposure to a medication containing a sulfonamide chemical group, well above the level at which symptoms become serious.6PubMed Central. A Rare Culprit of Methemoglobinemia While that specific case involved a different sulfonamide drug, the underlying chemistry is shared across the class, and sulfanilamide was recognized early on as a potential cause. Other blood-related problems included hemolytic anemia, in which the drug triggered destruction of red blood cells, and agranulocytosis, a dangerous drop in white blood cells that left patients vulnerable to overwhelming infections.
Severe Skin Reactions
Among the most feared complications are Stevens-Johnson syndrome and its more severe form, toxic epidermal necrolysis. These are immune-mediated reactions in which the skin and mucous membranes blister and slough off, sometimes over large areas of the body. They can be fatal. Sulfonamide antibiotics are one of the drug classes most strongly associated with these reactions. A landmark study found that the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis was roughly 172 times higher in people taking sulfonamide antibiotics compared with non-users.7PubMed. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis Case reports have continued to document these reactions, including incomplete forms of Stevens-Johnson syndrome triggered by sulfonamide antimicrobial exposure.8PubMed Central. Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure
Kidney Damage
Sulfanilamide and related sulfonamides can crystallize in the kidneys and urinary tract, particularly when patients are dehydrated or taking high doses. These crystals can obstruct the flow of urine and damage kidney tissue, sometimes leading to acute renal failure. This problem was well recognized during the drug’s heyday, and doctors routinely advised patients to drink large amounts of water while taking sulfonamides. Newer sulfonamide derivatives were eventually engineered to be more soluble, reducing but not eliminating this risk.
How Bacteria Fought Back
Perhaps the most important reason sulfanilamide lost its clinical relevance is bacterial resistance, which developed rapidly and spread widely. The mechanisms behind this resistance are now well understood and illustrate why older antimicrobials can become useless over time.
Resistance to sulfonamides arises in two main ways. The first is through point mutations in the gene that codes for the target enzyme, DHPS. When bacteria reproduce, random mutations occasionally change the shape of the enzyme’s active site just enough that sulfanilamide no longer fits snugly but the natural substrate still does. In laboratory settings, these resistant mutants are easy to generate, though the mutant enzyme often works less efficiently. In clinical infections, however, bacteria accumulate additional compensatory mutations that restore the enzyme’s normal function while maintaining resistance.9Drug Resistance Updates. Sulfonamide resistance: mechanisms and trends
The second and more clinically significant route is horizontal gene transfer. Bacteria can acquire entirely new genes, called sul genes, that encode alternative versions of the DHPS enzyme. These alternative enzymes are dramatically less sensitive to sulfonamides but still bind the natural substrate normally, meaning the bacteria can make folate unimpeded even in the presence of the drug. Two such genes, sul1 and sul2, are found at roughly equal frequency among resistant clinical isolates and are often carried on plasmids, small loops of DNA that bacteria swap between species like trading cards.9Drug Resistance Updates. Sulfonamide resistance: mechanisms and trends This plasmid-borne resistance is the primary reason sulfonamide resistance spread so quickly through gram-negative bacteria in hospitals and communities alike.10Nature Communications. Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics
Research into the structural details of how the DHPS enzyme works and how resistance mutations alter it has continued, partly because understanding these mechanisms could inform the design of new drugs that might overcome existing resistance.11PubMed Central. Catalysis and sulfa drug resistance in dihydropteroate synthase But for sulfanilamide powder itself, the ship has sailed. Resistance is too entrenched in too many bacterial species for the original compound to be useful.
Penicillin and the End of the Sulfanilamide Era
The arrival of penicillin in clinical practice during the early 1940s was the single biggest blow to sulfanilamide’s dominance. Penicillin was bactericidal, meaning it actively killed bacteria rather than merely halting their growth. It worked against many of the same pathogens sulfanilamide targeted, and for wound infections in particular, it proved dramatically more effective. By the end of World War II, penicillin had largely replaced sulfonamides as the frontline treatment for battlefield wounds, and civilian medicine followed suit.
Penicillin also had a more favorable side-effect profile for most patients. While penicillin allergy is real and sometimes serious, the drug did not carry the same risks of crystalluria, methemoglobinemia, or the extraordinarily high relative risk of Stevens-Johnson syndrome associated with sulfonamides. For clinicians choosing between the two classes, the calculus quickly became obvious.
Subsequent decades brought an expanding arsenal of antibiotics: tetracyclines, cephalosporins, aminoglycosides, fluoroquinolones, and many others. Each new class pushed sulfonamides further from the center of infectious disease treatment. Sulfanilamide powder in particular, with its limitations in contaminated wounds and its purely bacteriostatic action, had no compelling advantage over any of these newer options.
What Survived from the Sulfonamide Family
Sulfanilamide powder is gone, but the broader sulfonamide drug class is not entirely extinct. The combination of trimethoprim and sulfamethoxazole (often sold under the brand name Bactrim or Septra) remains on the World Health Organization’s list of essential medicines and is still widely prescribed for urinary tract infections, certain types of pneumonia, and some skin infections. This combination works because trimethoprim blocks a second enzyme in the same folate pathway, so bacteria face a double blockade that is harder to overcome with a single resistance mutation.
Silver sulfadiazine cream, another sulfonamide derivative, was for many years the standard topical treatment for burn wounds. Its use has declined in recent years as well, with studies questioning whether it actually improves healing compared with simpler wound dressings, but it remains available. Sulfasalazine, yet another relative, is used to treat inflammatory bowel disease and rheumatoid arthritis, though its therapeutic effect in those conditions comes from a different part of the molecule rather than from antibacterial activity.
These surviving sulfonamides share sulfanilamide’s basic chemical skeleton but have been modified to improve their solubility, extend their duration of action, or pair them with complementary drugs. None of them are applied as dry powder sprinkled into wounds. That particular method of delivery, while visually dramatic and deeply associated with wartime heroism, turned out to be one of the least effective ways to get a sulfonamide to do its job.
Why “Sulfa Allergy” Still Matters Today
One lasting legacy of sulfanilamide and its relatives is the widespread notation of “sulfa allergy” in patient medical records. Roughly three percent of the general population reports some form of adverse reaction to sulfonamide drugs, making it one of the most commonly listed drug allergies. The label can create confusion because the term “sulfa” gets applied loosely to a wide range of chemically distinct compounds. Sulfonamide antibiotics, sulfonamide diuretics, and even sulfate or sulfite preservatives in foods all share fragments of the word but do not necessarily trigger the same immune response.
A patient who had a genuine allergic reaction to sulfamethoxazole, for instance, does not automatically face the same risk from a sulfonamide-based blood pressure pill. The allergenic part of sulfonamide antibiotics is a specific chemical grouping (the arylamine group) that is not present on non-antibiotic sulfonamides. But because the “sulfa allergy” label is often recorded without specifying which drug caused the reaction or what the reaction was, many patients end up avoiding entire categories of medication unnecessarily. Clinicians now recommend documenting exactly which sulfonamide triggered the reaction and what symptoms it caused, rather than applying a blanket label.
For people who did experience severe reactions like Stevens-Johnson syndrome from a sulfonamide antibiotic, the caution is entirely justified. Given the extremely elevated risk identified in large studies, re-exposure to a drug from the same chemical subclass is genuinely dangerous.7PubMed. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis But for patients whose “sulfa allergy” amounts to mild nausea from a course of Bactrim twenty years ago, the restriction may be doing more harm than good by cutting off access to an effective and inexpensive antibiotic when they need one.
The Ongoing Search for Better Folate-Pathway Drugs
Researchers have not given up on the folate pathway as a target for antimicrobial drugs. The pathway remains absent in humans, which makes it an attractive point of attack, and the structural biology of the DHPS enzyme has been mapped in fine detail. Studies using crystallography and computational modeling have revealed exactly how the enzyme binds its natural substrate and where resistance mutations alter the binding pocket.11PubMed Central. Catalysis and sulfa drug resistance in dihydropteroate synthase The hope is that new compounds could be designed to fit the enzyme tightly enough that the common resistance mutations no longer provide an escape route.
Work on plasmid-borne resistance has added another layer of understanding. The alternative DHPS enzymes encoded by sul genes are structurally different enough from the normal bacterial enzyme that they shrug off sulfonamides completely, yet they still manage to bind the natural substrate with normal efficiency.10Nature Communications. Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics Understanding the precise molecular differences between these resistant enzymes and their susceptible counterparts could point the way toward drugs that inhibit both versions. Whether any of this will produce a new clinically useful drug remains to be seen, but the folate pathway has not been written off as a target just because sulfanilamide powder wound up in the history books.